Russell Jason K, Conley Alexander C, Wilson Jo Ellen, Newhouse Paul A
Department of Psychiatry and Behavioral Sciences, Center for Cognitive Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, Nashville, TN, USA.
Curr Top Behav Neurosci. 2025;69:49-78. doi: 10.1007/7854_2024_523.
Adults with Down syndrome represent the population with the highest risk of developing Alzheimer's disease worldwide. The cholinergic system is known to decline in Alzheimer's disease, with this decline responsible for many of the cognitive deficits that develop. The integrity of the cholinergic system across the lifespan in individuals with Down syndrome is not well characterized. Small fetal and infant post-mortem studies suggest an intact cholinergic projection system with a potential reduction in cholinergic receptors, while post-mortem studies in adults with Down syndrome reveal an age-related decrease in cholinergic integrity. Advances in magnetic resonance imaging (MRI) and positron emission tomography (PET) over the last 20 years have allowed for studies investigating the changes in cholinergic integrity across aging and during the development of Alzheimer's disease. One large cross-sectional study demonstrated reduced cholinergic basal forebrain volume measured by MRI associated with increasing Alzheimer's disease pathology. In a small cohort of adults with Down syndrome, we have recently reported that PET measures of cholinergic integrity negatively correlated with amyloid accumulation. New disease-modifying treatments for Alzheimer's disease and treatments under development for Alzheimer's disease in Down syndrome have the potential to preserve the cholinergic system, while treatments targeting the cholinergic system directly may be used in conjunction with disease-modifying therapies to improve cognitive function further. A greater understanding of cholinergic neuronal and receptor integrity across the lifespan in individuals with Down syndrome will provide insights as to when targeting the cholinergic system is an appropriate therapeutic option and, in the future, maybe a valuable screening tool to identify individuals that would most benefit from cholinergic interventions.
在全球范围内,患有唐氏综合征的成年人是患阿尔茨海默病风险最高的人群。已知在阿尔茨海默病中胆碱能系统会衰退,这种衰退是许多所出现的认知缺陷的原因。唐氏综合征患者一生中胆碱能系统的完整性尚未得到充分描述。小型胎儿和婴儿尸检研究表明胆碱能投射系统完整,但胆碱能受体可能减少,而对患有唐氏综合征的成年人的尸检研究显示胆碱能完整性存在与年龄相关的下降。过去20年中,磁共振成像(MRI)和正电子发射断层扫描(PET)技术的进步使得研究能够调查衰老过程以及阿尔茨海默病发展过程中胆碱能完整性的变化。一项大型横断面研究表明,通过MRI测量,胆碱能基底前脑体积减少与阿尔茨海默病病理学加重相关。在一小群患有唐氏综合征的成年人中,我们最近报告称,胆碱能完整性的PET测量值与淀粉样蛋白积累呈负相关。针对阿尔茨海默病的新型疾病修饰疗法以及正在为唐氏综合征患者研发的阿尔茨海默病治疗方法有可能保护胆碱能系统,而直接针对胆碱能系统的治疗方法可与疾病修饰疗法联合使用,以进一步改善认知功能。更深入了解唐氏综合征患者一生中胆碱能神经元和受体的完整性,将有助于了解何时靶向胆碱能系统是合适的治疗选择,并且在未来,可能成为一种有价值的筛查工具,以确定最能从胆碱能干预中受益的个体。